The Mitochondrial Protease LonP1 Promotes Proteasome Inhibitor Resistance in Multiple Myeloma

SIMPLE SUMMARY: Multiple myeloma is the second most common cancer of the blood system in the US. Despite new therapies, a cure remains elusive, and current drugs inevitably become ineffective due to various resistance mechanisms. A frontline clinical strategy is the inhibition of the proteasome, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Maneix, Laure, Sweeney, Melanie A., Lee, Sukyeong, Iakova, Polina, Moree, Shannon E., Sahin, Ergun, Lulla, Premal, Yellapragada, Sarvari V., Tsai, Francis T. F., Catic, Andre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7922145/
https://www.ncbi.nlm.nih.gov/pubmed/33671345
http://dx.doi.org/10.3390/cancers13040843

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7922145/
https://www.ncbi.nlm.nih.gov/pubmed/33671345
http://dx.doi.org/10.3390/cancers13040843

Ejemplares similares